Healthcare provider profile · identity verified

Marc Eisenbaum, M.D.

Internal Medicine · FAIRFAX, VA · NPI 1083710008

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Simvastatin	Simvastatin	473	147
Atenolol	Atenolol	224	66
Hydrochlorothiazide	Hydrochlorothiazide	218	69
Losartan Potassium	Losartan Potassium	214	68
Atorvastatin Calcium	Atorvastatin Calcium	209	72
Amlodipine Besylate	Amlodipine Besylate	168	55
Lisinopril	Lisinopril	168	49
Levothyroxine Sodium	Levothyroxine Sodium	152	48
Metformin Hcl	Metformin Hcl	148	43
Rosuvastatin Calcium	Rosuvastatin Calcium	130	43
Pravastatin Sodium	Pravastatin Sodium	88	29
Metoprolol Succinate	Metoprolol Succinate	80	25
Trazodone Hcl	Trazodone Hcl	74	22
Lorazepam	Lorazepam	69	27
Synthroid	Levothyroxine Sodium	67	21
Escitalopram Oxalate	Escitalopram Oxalate	64	21
Tamsulosin Hcl	Tamsulosin Hcl	55	22
Ozempic	Semaglutide	52	suppressed
Allopurinol	Allopurinol	49	16
Zolpidem Tartrate	Zolpidem Tartrate	47	18
Pantoprazole Sodium	Pantoprazole Sodium	46	17
Glimepiride	Glimepiride	45	15
Montelukast Sodium	Montelukast Sodium	42	14
Eliquis	Apixaban	39	15
Sertraline Hcl	Sertraline Hcl	37	12
Fenofibrate	Fenofibrate Nanocrystallized	36	suppressed
Amoxicillin	Amoxicillin	35	33
Ezetimibe	Ezetimibe	33	14
Valacyclovir	Valacyclovir Hcl	33	15
Januvia	Sitagliptin Phosphate	28	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	27	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	26	12
Olmesartan Medoxomil	Olmesartan Medoxomil	26	suppressed
Warfarin Sodium	Warfarin Sodium	26	suppressed
Gabapentin	Gabapentin	25	suppressed
Potassium Chloride	Potassium Chloride	25	13
Terbinafine Hcl	Terbinafine Hcl	25	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	25	suppressed
Alprazolam	Alprazolam	24	12
Finasteride	Finasteride	24	suppressed
Jardiance	Empagliflozin	24	suppressed
Clonazepam	Clonazepam	23	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	23	suppressed
Gemfibrozil	Gemfibrozil	22	suppressed
Labetalol Hcl	Labetalol Hcl	22	suppressed
Clopidogrel	Clopidogrel Bisulfate	21	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	21	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	21	suppressed
Fosinopril Sodium	Fosinopril Sodium	20	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	20	16
Prednisone	Prednisone	20	16
Methylprednisolone	Methylprednisolone	18	17
Omeprazole	Omeprazole	18	suppressed
Azithromycin	Azithromycin	17	17
Bupropion Xl	Bupropion Hcl	17	suppressed
Diazepam	Diazepam	17	suppressed
Valsartan	Valsartan	17	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	16	suppressed
Furosemide	Furosemide	16	suppressed
Irbesartan	Irbesartan	16	suppressed
Nabumetone	Nabumetone	16	suppressed
Tadalafil	Tadalafil	16	suppressed
Citalopram Hbr	Citalopram Hydrobromide	14	suppressed
Indapamide	Indapamide	14	suppressed
Mometasone Furoate	Mometasone Furoate	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	14
Meloxicam	Meloxicam	13	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	13	suppressed
Ramipril	Ramipril	13	suppressed
Spironolactone	Spironolactone	13	suppressed
Arnuity Ellipta	Fluticasone Furoate	12	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Doxepin Hcl	Doxepin Hcl	12	suppressed
Fluticasone Propionate	Fluticasone Propionate	12	suppressed
Klor-Con M20	Potassium Chloride	12	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	11	suppressed
Duloxetine Hcl	Duloxetine Hcl	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	11	11
Pregabalin	Pregabalin	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error